(Q33371515)

English

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

cardiac surgery

0 references

anticoagulation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shahid M Nimjee

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J R Keys

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G A Pitoc

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Quick

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C P Rusconi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bruce A Sullenger

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

9 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

408-415

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Cardiopulmonary bypass in humans: bypassing unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Direct effects of protamine sulfate on myocyte contractile processes. Cellular and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Allergy to protamine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Adverse events after protamine administration following cardiopulmonary bypass in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammatory response to cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

RNA aptamers as reversible antagonists of coagulation factor IXa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Antidote-mediated control of an anticoagulant aptamer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Role of thrombin signalling in platelets in haemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammation-coagulation network: are serine protease receptors the knot?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Inflammatory response to cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Negative inotropic effects of cytokines on the heart mediated by nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Mechanism of hepatocellular dysfunction during early sepsis. Key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Correlation between inflammatory response and markers of neuronal damage in coronary revascularization with and without cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.006

7 January 2021

Identifiers

10.1016/J.YMTHE.2006.04.006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371515&oldid=1979650424"